These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31557995)

  • 1. A Clinical Approach for Defining the Threshold between Low and Medium Anti-Cardiolipin Antibody Levels for QUANTA Flash Assays.
    Lakos G; Bentow C; Mahler M
    Antibodies (Basel); 2016 May; 5(2):. PubMed ID: 31557995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of automated chemiluminescent antiphospholipid antibody assay.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2015 Nov; 136(5):1033-9. PubMed ID: 26376037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Clinical Performance of a Novel Chemiluminescent Immunoassay for Detection of Anticardiolipin and Anti-Beta2-Glycoprotein 1 Antibodies in the Diagnosis of Antiphospholipid Syndrome.
    Zhang S; Wu Z; Li P; Bai Y; Zhang F; Li Y
    Medicine (Baltimore); 2015 Nov; 94(46):e2059. PubMed ID: 26579816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of patients with triple antiphospholipid antibody positivity is platform and method independent.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Pol Arch Med Wewn; 2016; 126(1-2):19-24. PubMed ID: 26810938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Novel Technologies for the Detection of Anti-cardiolipin and Anti β2-Glycoprotein Antibodies in the Real Life: Chemiluminescent in Comparison to the Addressable Laser Bead Immunoassays.
    Grossi V; Infantino M; Benucci M; Li Gobbi F; Bandinelli F; Damiani A; Bodio C; Borghi MO; Mahler M; Aure MA; Bentow C; Manfredi M
    Immunol Invest; 2020 Feb; 49(1-2):58-68. PubMed ID: 31401900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of antiphospholipid antibodies by enzyme immunoassay and chemiluminescent methods in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data).
    Cheldieva FA; Reshetnyak TM; Cherkasova MV; Lila AM
    Klin Lab Diagn; 2021 Sep; 66(9):546-551. PubMed ID: 34543533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of ELISA-comparable moderate and high thresholds for anticardiolipin and anti-β2 glycoprotein I chemiluminescent immunoassays according to the 2023 ACR/EULAR APS classification criteria and evaluation of their diagnostic performance.
    Žigon P; Boštic N; Ambrožič A; Rotar Ž; Blokar E; Ogrič M; Čučnik S
    Clin Chem Lab Med; 2025 Jan; 63(1):164-176. PubMed ID: 39044613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome.
    Persijn L; Decavele AS; Schouwers S; Devreese K
    Thromb Res; 2011 Dec; 128(6):565-9. PubMed ID: 21529896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of the first fully automated method for anti-cardiolipin and anti-beta2 glycoprotein I antibody detection for the diagnosis of antiphospholipid syndrome.
    Villalta D; Alessio MG; Tampoia M; Da Re A; Stella S; Da Re M; Tozzoli R; Bizzaro N
    Ann N Y Acad Sci; 2009 Sep; 1173():21-7. PubMed ID: 19758127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis.
    Sciascia S; Willis R; Pengo V; Krilis S; Andrade D; Tektonidou MG; Ugarte A; Chighizola C; Branch DW; Levy RA; Nalli C; Fortin PR; Petri M; Rodriguez E; Rodriguez-Pinto I; Atsumi T; Nascimento I; Rosa R; Banzato A; Erkan D; Cohen H; Efthymiou M; Mackie I; Bertolaccini ML;
    Thromb Res; 2019 Mar; 175():32-36. PubMed ID: 30685523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Performance of a New Chemiluminescent Immunoassay in Measuring Anti-β2 Glycoprotein 1 and Anti-Cardiolipin Antibodies.
    Zhou J; Hou X; Zhang H; Wang T; Cui L
    Med Sci Monit; 2018 Sep; 24():6816-6822. PubMed ID: 30256771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiphospholipid Antibody Testing in a Maximum Care Hospital: Method-Dependent Differences.
    Kocijancic M; Goj T; Peter A; Klein R; Hörber S
    J Clin Med; 2024 Aug; 13(15):. PubMed ID: 39124794
    [No Abstract]   [Full Text] [Related]  

  • 14. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.
    Vandevelde A; Chayoua W; de Laat B; Gris JC; Moore GW; Musiał J; Zuily S; Wahl D; Devreese KMJ
    J Thromb Haemost; 2022 Feb; 20(2):508-524. PubMed ID: 34758192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of antibodies to beta2-glycoprotein 1 from patients with systemic lupus erythematosus.
    Cabral AR; Cabiedes J; Alarcón-Segovia D
    Lupus; 2004; 13(3):182-7. PubMed ID: 15119547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome.
    Mondejar R; González-Rodríguez C; Toyos-Sáenz de Miera FJ; Melguizo-Madrid E; Zohoury N; Mahler M; Romero Losquiño I; Fabiani F
    Clin Chim Acta; 2014 Apr; 431():174-8. PubMed ID: 24522162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical significance of antiphospholipid antibody measured by EliA anticardiolipin antibodies and anti-β2Glycoprotein I antibodies in antiphospholipid syndrome].
    Fujieda Y; Shida H; Oku K; Bohgaki T; Amengual O; Horita T; Yasuda S; Atsumi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(5):430-6. PubMed ID: 25744643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests.
    Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC
    J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual.
    Frodlund M; Vikerfors A; Grosso G; Skogh T; Wetterö J; Elvin K; Gunnarsson I; Kastbom A; Dahlström Ö; Rönnelid J; Svenungsson E; Sjöwall C
    Clin Exp Immunol; 2018 Oct; 194(1):27-38. PubMed ID: 30208508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.